There are still a lot of unknowns in terms of funding amounts and consolidations. I am more than happy to wait this one out and see where it winds up. There could be many reasons why Dr Porter walked away especially with his significant duties regarding RAP. ePat is also initially focusing on dementia patients and Dr Porter is a pediatrcian at Joondolup - there possibly wasn't a role for him this early in development.
My understanding is that ePat is also has been initially trailed at Joondolup hospital, the same initial trial point as ResApp.
It will be interesting to see what unfolds - the Product too cheap to ignore.
MNQ Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
